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Abstract: Recent findings indicate a significant association between sedentary (SED)-time and type 
2 diabetes mellitus(T2DM). The aim of this study was to investigate whether different levels of 
SED-time could impact on biochemical and physiological processes occurring in sedentary and 
physically inactive T2DM patients. In particular, patients from the “Italian Diabetes and Exercise 
Study (IDES)_2 trial belonging to the first and fourth quartile of SED-time were compared. Urine 
samples were analyzed by comprehensive two-dimensional gas chromatography(GC×GC) with 
parallel detection by mass spectrometry and flame ionization detection(GC×2GC-MS/FID). This 
platform enables accurate profiling and fingerprinting of urinary metabolites while maximizing the 
overall information capacity, quantitation reliability, and response linearity. Moreover, using 
advanced pattern recognition, the fingerprinting process was extended to untargeted and targeted 
features, revealing diagnostic urinary fingerprints between groups. Quantitative metabolomics 
was then applied to analytes of relevance for robust comparisons. Increased levels of glycine, 
L-valine,L-threonine, L-phenylalanine, L-leucine, L-alanine, succinic acid, 2-ketoglutaric acid, 
xylitol, and ribitol were revealed in samples from less sedentary women. In conclusion, SED-time is 
associated with changes in urine metabolome signatures. These preliminary results suggest that 
reducing SED-time could be a strategy to improve the health status of a large proportion of diabetic 
patients. 
Keywords: sedentariness; urine metabolome; type 2 diabetes; observational study; comprehensive 
two-dimensional gas chromatography; dual parallel detection by mass spectrometry and flame 
ionization detector; chemometrics 
 
1. Introduction 
Type 2 diabetes mellitus (T2DM) is one of the most widespread diseases in the world [1]. It is a 
complex metabolic disorder with multiple causes and there is compelling evidence which indicates 
that a physically active lifestyle can reduce cardiovascular risk factors and improve glycemic control 
and well-being in people with T2DM [2–7]. Physical activity (PA) is considered a cornerstone of the 
prevention and management of this disease. However, a significant association between sedentary 
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(SED)-time and metabolic risk was recently observed in T2DM patients, independently of several 
confounders, including time spent in moderate-to-vigorous-intensity PA (MVPA). Indeed, after 
accounting for SED-time, MVPA was not associated with clustered metabolic risk [8,9]. These data 
are consistent with previous reports showing that daily sitting time or television viewing were 
positively associated with all-cause and cardiovascular mortality [10,11], as well as cardiovascular 
risk factors [12,13]. Taken together, these observations support the concept that physical inactivity 
and sedentary behavior negativelyaffect health status through distinct pathways thus highlighting 
the need to reduce SED-time in addition to increasing PA. 
Notably, SED-time is not related to the time spent in PA. Indeed, the term “sedentary behavior” 
differs from “physical inactivity” [14]. In keeping with the Sedentary Behavior Research Network, 
sedentary behavior is defined as “any waking behavior characterized by an energy expenditure ≤1.5 
METs (multiples of the resting metabolic rate, defined as an oxygen uptake of 3.5 mL/kg/min) while 
in a sitting or reclining posture” [15,16], whereas the term “physical inactivity” refers to not 
achieving the minimum recommendations of moderate-to-vigorous physical activity [17]. 
Although the majority of epidemiological studies have focused on the effect of PA, rather than 
on the reduction of SED-time, theattention on the deleterious consequences of prolonged SED-time 
has been recently intensified, with strong evidence linking SED-time to an increased risk of T2DM 
development [18,19]. Previous studies haveshown a positive correlation between SED-time and high 
glucose levels [20] or insulin resistance [8], andthat interrupting prolonged sitting in T2DM people 
improved the glycemic control [21,22]. 
One comprehensive approach to evaluate the systemic metabolism, reflecting the metabolic 
health of an individual, is using metabolomics. Its importance to evaluate early changes in 
metabolite profiles related to metabolic disease, in particular diabetes [23,24] is well known. 
Interestingly, more recently, metabolomics have been also adopted to identify pathways involved in 
the beneficial effects evoked by physical activity [25–28]. In contrast, very limited data are available 
on SED-time and its potential ability to affect the metabolic fine print (i.e., fingerprint) in 
biofluids[29]. In particular, to the best of our knowledge, the effect of SED-time has been not 
investigated in urine metabolomic profiles. 
Within this challenging context, this study on urinary metabolic signatures could provide some 
insight on the mechanisms underlying the impact of sedentary behavior on systemic metabolism, 
and provide further information on individual response[30–32]. To accurately track changes and/or 
to monitor the evolution of primary metabolites in urine samples, comprehensive two-dimensional 
gas chromatography coupled with mass spectrometry (GC×GC-MS) represents one of the most 
advanced and informative GC platforms currently available [33]. Its separation power, sensitivity, 
and structured bi-dimensional (2D) patterns generated for chemically correlated compounds are 
fundamental keyfeatures at the basis of its information potential for complex biological samples’ 
profiling and fingerprinting [30,33–35]. 
For this study, a GC×GC system with parallel dual secondary column-dual detection 
configuration (GC×2GC-MS/FID) was adopted to maximize the overall information capacity [36,37] 
by improving quantitation reliability and response linearity. In addition, advanced pattern 
recognition methodologies based on the 2D data were employed, extending the investigation to 
untargeted and targeted 2D-peak features for the most inclusive fingerprinting (i.e.,UT 
fingerprinting) [30,38]. 
This study aimed to investigate whether in sedentary and physically inactive patients with 
T2DM, different levels of SED-time could affect the urinary metabolic signatures in order to better 
understand the biological pathways potentially linking the prolonged SED-time to T2DM. To this 
purpose, we selected a sub-group of T2DM patients enrolled in the Italian Diabetes and Exercise 
Study (IDES)_2 study [39] and examined urine samples using the following procedure. 
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2. Results 
2.1. Characteristics of Study Patients 
The study population was a subgroup (n=86) of T2DM patients previously enrolled in the 
IDES_2 clinical trial[39]and was separated into two different groups: Group 1, the less sedentary 
group, belonging to the first quartile of SED-time; Group 2, the more sedentary group, belonging to 
the fourth quartile of SED-time (Table 1, Table S1). Demographic and clinical parameters of the two 
selected study population groups are reported in Table 2. 
Table 1.Criteria selected for the study groups generation (Group 1: The less sedentary(SED) group, 
belonging to the first quartile of SED-time, and Group 2: The more sedentary group, belonging to the 
fourth quartile of SED-time). 
 Group 1 Group 2 P Value 
Sleep duration, h/day  8.04 ± 0.58 8.78 ± 0.95 *** p<0.0001 
Sedentary time h/day  11.10 ± 1.02 12.57 ± 0.95 *** p<0.0001 
Light-intensity activity h/day  4.63 ± 1.10 2.52 ± 1.14 *** p<0.0001 
Mod.- to Vig. intensity activity by 
accelerometer and diary h/day 
0.23 ± 0.07 0.13 ± 0.08 *** p<0.0001 
***p < 0.001 Group2 vs Group 1. 
 Table 2.Demographic and clinical parameters of study patients. 
Clinical Parameters Group 1 Group 2 P Value 
Age, years 57.09 ± 7.99 67.98 ± 10.32 *** p<0.0001 
Gender: male 
female  
22 (51.2%) 
21 (48.8%) 
20 (46.5%) 
23 (53.5%) 
p>0.050 
Weight, kg  79.64 ± 15.00 84.87 ± 15.88 p>0.050 
BMI, kg/m2 28.56 ± 4.72 30.95 ± 5.21 * p=0.030 
Systolic BP, mmHg 136.70 ± 21.06 148.35 ± 22.69 * p=0.039 
Diastolic BP, mmHg 82.44 ± 10.03 83.72 ± 16.63 p >0.050 
HbA1c, % 7.34 ± 1.53 7.83 ± 1.83 p >0.050 
Fasting Plasma Glucose,mg/dl  135.28 ± 49.21 142.65 ± 60.31 p >0.050 
Insulin, µU/ml 10.94 ± 10.76 13.33 ± 9.97 p >0.050 
HOMA-IR  3.48 ± 2.99 4.41 ± 3.20 p>0.050 
Triglycerides, mg/dl  182.40 ± 256.01 177.05 ± 79.64 * p=0.011 
Total cholesterol, mg/dl 184.21 ± 36.16 171.63 ± 44.61 p>0.050 
HDL cholesterol, mg/dl 48.44 ± 14.93 45.30 ± 13.34 p>0.050 
LDL cholesterol, mg/dl  115.88 ± 36.62 100.12 ± 36.63 p>0.050 
UKPDS CHD 
10-year risk score  
 
14.79 ± 9.48 
 
27.89 ± 17.52 
 
*** p<0.0001 
UKPDS FATAL CHD 
10-year risk score 
 
9.62 ± 7.39 
 
22.51 ± 16.49 
 
*** p <0.0001 
UKPDS STROKE  
10-year risk score 
 
7.27 ± 6.29 
 
21.84 ± 16.27 
 
*** p <0.0001 
UKPDS FATAL STROKE  
10-year risk score 
 
1.14 ± 1.09 
 
3.84 ± 3.34 
 
*** p <0.0001 
* p < 0.05; ***p < 0.001 Group2 vs Group 1. 
Significant differences between the groups were observed for age and, as it could be expected, 
for BMI, triglycerides, systolic blood pressure, and cardiovascular risk scores. Within the same 
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gender (female 1 vs.female 2 or male 1 vs.male 2, Table S2) differences between the two groups for 
age and cardiovascular risk scores in both males and females were observed, whereas triglycerides 
and blood pressure were different just within group for women. 
2.2. Urinary Metabolic Signatures: Bottom-Down Approach for Target Candidates’ Selection 
The first step of the data elaboration work-flow based on the chemical/metabolic fingerprints 
aimed at delineating, if possible, natural groups’ conformation within the set of individuals’ urinary 
signatures. A first elaboration was performed by considering all available samples, including 
analytical replicates, and for each sample, all untargeted and targeted peak-regions (UT) 
corresponding to all detected compounds reliably matching across all 2D patterns. Data 
normalization was by ISTDsand total analytical response. Analytes’ quantitative descriptors were 
thus 2D-nomalized volumes % (i.e., 2D peak volumes divided by ISTD response and subsequently 
normalized over the total analytical response %). The resulting data matrix was 152×850 (samples x 
UT features). When submitted to unsupervised PCA (principal component analysis), the resulting 
score-plot (Figure 1) did not show any clear clustering between the two groups, suggesting the 
presence of several confounding variables not strictly related to the phenomenon under study (i.e., 
SED-time). 
 
Figure 1.Principal component analysis (PCA) scores-plot based on all detected peak-region features 
over the entire sample set. Group 1 (less sedentary group) and Group 2 (more sedentary group) were 
depicted as circles and triangles, respectively. Different colors were used to indicate males (blue and 
yellow) and females (gray and dark red). Small and large (with a black spot) symbols represent 
individual and mean values, respectively. 
Thereby, as second step, a supervised approach through orthogonal partial least 
square-discriminant analysis (OPLS-DA) was applied on all UT peak-features to see the differential 
effect of sedentariness on genders. OPLS-DA correlation spectrum showed a positive correlation 
between each variable in the x block (untargeted peak-features) with y variables (samples grouped 
in gender and treatment). With this function, the graphical exclusions of poorly correlating x 
variables was facilitated. 
The aim of this supervised exploration was to better outline those variables mostly related to 
the treatment,while reducing the noise from confounding factors, rather than to develop a 
classification model. The sample set was not sufficient to perform a fullvalidation and the risk of 
overfitting was expected. However, the strategy allowed effective selection of variables, i.e., targeted 
analytes to be quantified with suitable accuracy and precision by GC-MS. Results, shown in Figure 2, 
suggest that among females, as compared with males, the effect of sedentariness has a greater 
impact on urinary metabolic signatures.Model performances referred of: (1) 94% accuracy for 
females and 100% for males, (2) 93.8% sensitivity for females and 100% for males, and (3) 
100%specificity for both gender groups. 
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Figure 2.Two-by-two orthogonal partial least square-discriminant analysis (OPLS-DA) of the  
combined untargeted and targeted UT peak-region features filtered by Fisher ratio from the whole 
samples’ set. Group 1 (less sedentary group) and Group 2 (more sedentary group) were depicted as 
circles and triangles, respectively. Different colors were used to indicate males (panel A, blue and 
yellow) and females (panel B, gray and dark red). Small and large (with a black spot) symbols 
represent individual and mean values, respectively. 
Results from OPLS-DA correlation spectra enabled feature selection toward target analytes that 
were thus submitted, in the third step, to quantitative metabolomics by GC-MS. Quantitation was 
also extended to some additional metabolites selected after a careful survey of the scientific literature 
within those metabolic markers with relevant information potential. 
Quantitative results, normalized over creatinine concentration, are reported as supplementary 
information (Table S3). Data were submitted to supervised linear discriminant analysis (LDA) to 
facilitate the evidence of meaningful variables between groups and for each gender. Table 3 reports 
metabolites percentage of variation referred to the median relative increment/decrement of the 
Group 1 vs. Group 2. 
Table 3.Metabolites significantly increased in the Group 1 vs. Group 2. 
Metabolites 
% of Increase 
Vs. Group 2 
FEMALES  
Glycine  312 
L-Alanine 85 
L-Valine 65 
L-Leucine  55 
2-Ketoglutaric acid 54 
L-Threonine 47 
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L-Phenylalanine 40 
Succinic acid 33 
Ribitol 31 
Xylitol  25 
 
In females belonging to the less sedentary group (Group 1), it was observed a relevant 
up-regulation of several urinary metabolites: Glycine (§p =0.011), L-alanine (p = 0.042), 2-ketoglutaric 
acid (p = 0.011), L-threonine (§p = 0.041), L-valine (§p = 0.029), succinic acid (p = 0.031), 
L-phenylalanine (p = 0.014), L-leucine (p = 0.024), xylitol (p = 0.015), and ribitol (p = 0.018). The 
information power of the selected metabolites was assessed by Kruskal–Wallis test followed by the 
Dunn’s comparison of the mean (P) and Bonferroni correction (§p). 
3. Discussion 
In this study patients were evaluated by monitoring the relationship between SED-time and 
urinary metabolome. An initial analysis of our data using PCA revealed no clearly distinguishable 
differences in urine metabolic signature in relation to SED-time. However, LDA analysis showed 
some differences between the two groups, in particular among females, who appeared more 
responsive than males to the different levels of SED-time. This observation is not surprising[40] since 
previous studies also showed more pronounced plasma metabolite changes correlated to physical 
activity among females rather that in males [25,26].Although previous studies have evaluated the 
effects of SED-time on plasma metabolomic profiles[26,41],this study presents for the first time an 
observed effect of SED-time on urine metabolites and attempts to give a clinical meaning to the 
relationship between reduced SED-time and T2DM. 
In order to evaluate whether metabolite changes observed in less sedentary diabetic women 
could affect their health status, our results attempted to correlate metabolomic analysis to T2DM. 
Xiao et al. and Fukai et al. have shown a lower aminoacids plasma level in people at the lower 
level of sedentariness. Although insulin resistance and diabetes development show a positive 
correlation with high plasma levels of branched chain amino acids (BCAAs, valine, leucine, 
isoleucine) [42,43], the causal link is still under debate [44]. Several groups have provided 
mechanistic explanations for this correlation. In particular, insulin resistance is evoked by an excess 
of the catabolic flux of BCAA, rather than theplasma level [45]. This data is supported by Menni C. et 
al. [46], according to whom diabetes is more related tothe breakdown of BCAA, rather than the 
elevated level of these aminoacids. 
The first step of BCAA catabolic pathways is the reversible transamination reaction that 
converts them into branched-chain ketoacids. The pair glutamate/2-ketoglutarate is necessarily 
involved in this process. Indeed, BCAA transfer the amino group to2-ketoglutarate, thus converting 
it into glutamate [47]. Interestingly, our data showed a higher level of 2-ketoglutaric acid in the urine 
of the less sedentary women, thus allowing us to hypothesize a lower level of BCAA catabolism in 
these patients. As BCAA catabolism is positively correlated to insulin resistance, this data could 
indicate anincreased insulin sensitivity in less sedentary women. In support of this observation, 
2-ketoglutaric acid was also recently indicated as a urine marker of T2DM. Indeed, lower 
concentrations of this metabolite are found in urine samples of diabetics compared to healthy people 
[48]. Similar results were also seen in preclinical studies [49]. 
Few data are reported in the literature on the level of aminoacids in the urine of diabetic 
patients. Salek et al. [50] showed a decrease in the excretion of several aminoacids, including valine 
and leucine, in the urine of diabetic patients. Interestingly, an increase of amino acid concentration in 
the urine has been also observed in diabetic patients following rosiglitazone treatment [51], thus 
suggesting that this change could be associated to the pharmacological treatment that, by reducing 
insulin resistance, also decreases the demand for amino acids as substrates for gluconeogenesis. 
Therefore, the increased aminoacid excretion observed in less sedentary women could be suggestive 
of a minor need of glucose synthesis and, accordingly, improved insulin sensitivity. 
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In comparison to healthy subjects, T2DM patients exhibit a decreased excretion of some 
intermediates of the tricarboxylic acid (TCA) cycle, which could indicate a mitochondrial 
dysfunction [51–53]. Interestingly, in our study we observed a higher level of succinic acid, as well as 
2-ketoglutaric acid, in the urine of females belonging to the lower sedentary group. This data 
possibly indicate that SED-time reduction could exert a positive effect on the health status. 
We also found ameaningful increase in glycine level in the urine of the femalesin the lower 
sedentary group. Glycine could result from the action of the alanine-glyoxylate aminotransferase-2 
(AGT-2)on its substrate glyoxylate [54]. AGT-2 has been shown as having an important action in the 
blood pressure regulation[55]. Indeed, a suppression of the activity of this enzyme could be 
associated with hypertension and increased glyoxylate levels [56]. In contrast, by observing 
increased level of glycine in the urine in less sedentary women, we can speculate that the activity of 
this enzyme is higher in these patients. Notably, in keeping with these observations, as reported in 
Table S2, less sedentary females presented a significantly lower blood pressure value (p <0.050) in 
comparison with more sedentary women. The increased glycine excretion could contribute, at least 
in part, to this effect. 
Overall, our urinary metabolomic data allowed us to hypothesize that SED-time reduction may 
exert a positive effect on the health status. Thus we could suggest that limiting SED-time could be a 
useful strategy in particular for females, the group that has been demonstrated to be an independent 
predictor of failure to achieve therapeutic targets in diabetic patients [57]. 
This study had some limitations. First, we cannot exclude the possibility that the significant 
difference in terms of age, light PA, and MVPA levels between the two groups could have affected 
our results. Second, the cross-sectional nature of our study did not allow us to formulate causal 
relationship. However, our promising findings may inform future perspective investigations on the 
effect of SED-time reduction especially in longitudinal studies, which might lead to better 
understand the clinical meaning of this strategy and infer more solid conclusions. Finally, our results 
indicated that SED-time could affect the concentration of urinary metabolites, in particular in 
females, the most responsive gender, suggesting that lower level of SED-time could be associated to 
better T2DM outcome. Whether our data will be confirmed by ad hoc longitudinaltrials,SED-time 
reduction could become a positive and intriguing opportunity for diabetic patients. Indeed, it is well 
known that increases of physical activity lead to major beneficial effects in these patients, but 
unfortunately, compliance is quite low. The possibility to achieve significant results with minimal 
efforts could encourage the patients to improve their adherence to the lifestyle indications suggested 
by physicians, with consequently better outcomes. 
4. Materials and Methods 
4.1. Study Population 
Study population included men and women from the IDES_2 trial [39].We selected a subgroup 
of physically inactive and sedentary patients (n=86) in order to compare patients at the first quartile 
of SED-time (n=43) towards those at the fourth quartile (n=43 ). The main entry criterion was T2DM 
(defined by the ADA criteria [58]) of at least one-year duration. Additional requirements were: Age 
40–80 years, body mass index 27–40 kg/m2 (i.e., insufficient amounts of PA according to current 
guidelines [59]) and sedentary lifestyle (i.e., >8 h/day [60]) from at least 6 months, ability to walk 1.6 
km without assistance, and eligibility after cardiologic evaluation. At inclusion in the studyT0, 
patients’24-hurine was collected and conserved at –20°C until analysisas baseline data. 
All subjects gave informed consent for inclusion before participation in the study IDES_2. This 
study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved 
by the ComitatoEticodell’AziendaOspedalieraSant’Andrea Prot. n. 212/2012 (ClinicalTrials.gov; 
NCT01600937; 10 October 2012). 
4.1.1. Measurements of Sedentariness 
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At baseline, MVPA, LPA, and SED-time were measured by the use of an accelerometer 
(MyWellness Key, Technogym, Cesena, IT), which was validated versus Actigraph [61] and 
provided accurate measures of the minutes spent at different intensities and the total PA volume [6], 
even in individuals with T2DM [62]. A daily diary was kept for reporting the time spent wearing the 
instrument, sleeping and napping, and performing non-accelerometer recordable PAs such as 
swimming, cycling, skiing, etc. Participants were asked to attach the device at the waist and to wear 
it all day (except if swimming) up to bedtime, in order to avoid the influence of the “time 
accelerometer worn”, which may cause underestimation of daily SED-time. In this way, it was 
possible to assume that time patients were awake without wearing the accelerometer was spent in 
routine morning and evening sedentary activities, unless spent in PAs that cannot be performed 
while wearing the accelerometer (e.g., swimming). Total SED-time was then calculated by adding 
this time to that recorded by the accelerometer. Time spent in non-accelerometer recordable PAs, as 
reported on the diary, was added to that recorded by the accelerometer, according to the intensity of 
each activity. Measurements for seven consecutive days were obtained at baseline. Participants were 
evaluated for physical fitness by assessing cardio-respiratory fitness (as maximal oxygen uptake, 
VO2max), strength, and flexibility by maximal treadmill exercise test, isometric test, and bending 
test, respectively [63,64]. 
4.2. Urine Metabolites’Fingerprinting 
4.2.1. GC×2GC-MS/FID Instrument Setup 
GC×GC analyses were run with a MPS-2 multipurpose auto-sampler (Gerstel GmbH, Germany) 
integrated with an Agilent 6890 GC unit coupled to an Agilent 5975C MS detector (Agilent, Little 
Falls, DE, USA) operating in EI mode at 70 eV. The GC transfer line was set at 300°C. An auto-tune 
option was used and the scan range was set to m/z 50–450 with a scanning rate of 12,500 amu/s to 
obtain a spectra generation frequency of 20 Hz. The flame ionization detector (FID) was operated as 
follows: Base temperature 300°C, H2 flow 40 mL/min, air flow 350 mL/min, make-up (N2) 20 
mL/min, and sampling frequency 200 Hz. 
The column set consisted of a first-dimension (1D) column of 30 m×0.25 mm dc×0.25 µmdf SE52 
(95% polydimethylsiloxane, 5% phenyl) coupled to two second-dimension (2D) columns of 
equivalent length of 1.4 m×0.1 mm dc×0.10 µmdfOV1701 (86% polydimethylsiloxane, 7% phenyl, 7% 
cyanopropyl). Connections between the primary and the two secondary columns were by a 
SilFlow™ GC 3 Port Splitter (Trajan Scientific and Medical, Ringwood Victoria, Australia). The 
secondary column toward the MS detector was connected to a Quick Swap unit (G3185, Agilent, 
Little Falls, DE, USA) and to an auxiliary electronic pressure controller (EPC) consisting of a 
one-channel Pneumatics Control Module (G2317A, Agilent, Little Falls, DE, USA). The restrictor 
capillary in the GC-MS transfer line was of 0.17 mx0.1 mm dc. All columns and capillaries were from 
Mega (Legnano, Milan, Italy). Helium carrier gas was delivered at constant flow with initial head 
pressure pi 255.0 KPa and the auxiliary gas (He) for MS outlet pressure correction was delivered at a 
relative pressure of 39.9 KPa. The estimated split ratio between MS/FID was 50:50. Details on the 
system configuration have been previously published[36]. 
Injections for the analysis of both urine samples and n-alkanes for linearretention indices 
determination ITs,were by a MPS-2 sampler (Gerstel GmbH, Germany) under the following 
conditions: Split/splitless injector, pulsed split mode, split ratio 1/20, injector temperature 290°C, and 
injection volume 2µL. The oven temperature program was 60°C (1 min) to 300°C (10 min) at 
4.0°C/min. 
The system was equipped with a two-stage KT 2004 loop-type thermal modulator (Zoex 
Corporation, Houston, TX) cooled with liquid nitrogen and controlled by Optimode™ V.2 (SRA 
Instruments, CernuscosulNaviglio, MI, Italy). The hot jet pulse time was set at 350 ms, modulation 
time was 5 s, and the cold-jet total flow was progressively reduced with a linear function from 30% 
of mass flow controller (MFC) at initial conditions to 5% at the end of the run. Loop dimensions were 
chosen on the basis of the expected carrier linear velocities to ensure that two-stage band focusing 
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and release were performed for each modulation stage. The first 0.6 m of the 2Ds were wrapped in 
the metal slit of the loop-type modulator. 
4.2.2. GC-MS Instrument Setup 
GC-MS analyses were run for quantitative purposes with the following system configuration: 
An MPS-2 multipurpose auto-sampler (Gerstel GmbH, Germany) was integrated with an Agilent 
6890 GC unit coupled to an Agilent 5975C MS detector (Agilent, Little Falls, DE, USA) operating in 
EI mode at 70 eV. The GC transfer line was set at 300°C. An auto-tune option was used and the scan 
range was set to m/z 35–550 with a scanning rate of 2500 amu/s. 
The column consisted of 30 m × 0.25 mm dc × 0.25 µmdf SE52 (95% polydimethylsiloxane, 5% 
phenyl) from Mega (Legnano, Milan, Italy). The carrier gas was helium delivered at constant flow 
(1.0 mL/min) with initial head pressure pi 255.0 KPa. 
Injections for the analysis ofurine samples, standard calibration solutions, and n-alkanes for 
linear retention indices determination IT were by a MPS-2 sampler (Gerstel GmbH, Germany) under 
the following conditions: Split/splitless injector, split mode, split ratio 1/20, injector temperature 
290°C, and injection volume 2µL. The oven temperature program was 80°C (2 min) to 140°C at 
10.0°C/min then to 240°C at 4°C/min up to 290°C (5 min) at 10°C/min. 
4.2.3. Raw Data Acquisition and GC×GC Data Handling 
Data were acquired by Agilent MSD ChemStationver E.02.01.00 and processed using GC Image 
GC×GC Software version 2.7 (GC Image, LLC Lincoln NE, USA). 
4.2.4. UT Fingerprinting Work-Flow 
The 2D data elaboration work-flow is illustrated in Supplementary Figure 1 (SF1). It was 
optimized and validated in previous studies dealing with complex samples of different natures. It 
combines untargeted and targeted pattern recognition approaches for the most inclusive 
fingerprinting. 
Steps correspond to the different phases of data elaboration where supervised methods were 
combined with unsupervised and automated procedures. 
The 2D-data processing was by template-matching strategy developed by Reichenbach et al. 
[65]. In this approach, 2D peak patterns’ metadata (retention times, MS fragmentation, and detector 
responses) were collected and adopted to establish correspondences between the same analyte 
across multiple chromatograms. Aligned 2D peaks and 2D peak-regions together with related 
metadata were made available for comparative purposes and further processing [66,67]. 
Targeted analysis (Step 1,SF 1) was based on urinary metabolites reliably identified by 
matching EI-MS fragmentation pattern (NIST MS Search algorithm, ver 2.0, National Institute of 
Standards and Technology, Gaithersburg, MD, USA, with direct matching threshold 900 and reverse 
matching threshold 950) with those available in commercial (NIST2014 and Wiley 7n) and in-house 
databases. Linear retention indices (IT) along the 1D were adopted as additional constraint for 
positive identification (±10 units). 
Untargeted analysis (Step 2, SF 1) was by GC Image Investigator™ R2.7 (GC-Image LLC, 
Lincoln NE, USA) and considered 2D peak-regions features [68]above a response threshold of 5000 
counts (TIC current). Information about targeted/identified analytes from Step 1was combined to 
achieve the most inclusive fingerprinting (untargeted/targeted (UT) fingerprinting). This approach 
aligned all chromatograms using a set of registration peaks to produce a composite chromatogram 
from which feature peak-regions were extracted. Then, the template with untargeted peak-regions 
and targeted2D peaks was aligned with each of the chromatograms of the set for quantitative 
evaluation. Response data were used for multivariate analysis (MVA). 
4.2.5. Quantitative Profiling by GC-MS: Method Performance Verification 
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Validation of the GC-MS quantitative method followed a previous protocol [31] on a 
three-weeks-over-two-months period. Method figures of merit considered were: Precision, linearity, 
accuracy, and limit of quantitation (LOQ) (Commission, 2002; Eurachem, 2014). Precision data 
(intra- and interweek precision on retention times and 2D peak volumes on analytes’ target ions (Ti)) 
were evaluated by replicating analyses during the entire period. Linearity was by linear regression 
analyses within the working range, over at least six different concentration levels. 
Calibration solutions for quantitative determination were prepared by mixing 
single-component standard mother solutions at 10 g/L in suitable solvents (acetone or toluene) and 
adjusting the final volume up to the required concentration. Each solution was then submitted to 
derivatization (Section 4.2.6) and directly analyzed. Calibration levels investigated were: 100 mg/L, 
40 mg/L, 30 mg/L, 15 mg/L, 10 mg/L, 5 mg/L, 1 mg/L, 0.5 mg/L, and 0.1 mg/L. The 
4-fluorophenylalanine, i.e., the internal standard for derivatization quality control was at 10 mg/L. 
4.2.6. Reference Materials and Derivatization Procedures 
All chemicals were obtained from Merck (Milan, Italy): 
(1) Pure standards of n-alkanes (from n-C9 to n-C25) for system evaluation and linear 
retention index (IT) determination; 
(2) Pure standards for quantitative determinations and/or identity confirmation of 
pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, 2-ketoglutaric acid, 
L-alanine, L-valine, L-leucine, L-proline, glycine, L-threonine, L-tyrosine, 
L-phenylalanine, xylitol, ribitol, fructose, galactose, glucose, mannitol, myo-inositol, 
glycerol, creatinine, and the internal standards (ISTDs) 4-fluorophenylalanine (QC 
for derivatization), and 1,4-dibromobenzene (QC for GC normalization); 
(3) Derivatization reagents O-methylhydroxylamine hydrochloride (MOX) and 
N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA); and 
(4) HPLC-grade solvents: Methanol, pyridine, n-hexane, dichloromethane, and toluene. 
Urine samples were submitted to a standard derivatization protocol[69] consisting of the 
following steps: 80 µL of urine and a suitable volume of ISTD (4-fluorophenylalanine solution at 10 
g/L) were carefully mixed (Whirlimixer vortex, Fisher Scientific, Loughborough, Leicestershire, UK). 
Then, the solution was dried under a gentle stream of nitrogen before the addition of 60 µL of MOX. 
The resulting solution was incubated for 2 h at 60°C. Next, 60 µL of MSTFA were added and the 
mixture was incubated at 60 °C for one hour. The resulting sample solution was spiked with 
1,4-dibromobenzene at 50 mg/L final concentration and diluted in toluene. Analyses were 
immediately run by duplicate injections for each sample; samples were randomized within a 24-h 
time frame after derivatization. 
4.3. Statistical Analysis 
All values in both text and tables were expressed as meansd. Statistical significance was 
assessed by the Student’s t test for parametric data distribution or by Kruskal–Wallis combined to 
Dunn’s test (p) and Bonferroni correction (§p) for nonparametric data distribution. Testswere 
performed using the GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, 
California, USA) and XLSTAT (Addinsoft, New York, NY USA). 
Untargeted/targeted GC×GC features’ data were processed by Pirouette®® version 4.5 
(Infometrix, Inc., WA). Graphical analyses were performed using the R statistical and programming 
language (3.2.2) (https://cran.r-project.org/) and some add-on packages including ggplot2 and 
ggpubr. 
Supplementary Materials: The following are available online at www.mdpi.com/2218-1989/10/5/205/s1. Table 
S1: Criteria selected for the study groups’ generation, gender differences. Table S2: Demographic and clinical 
parameters of study patients, gender differences. Table S3: List of identified urine metabolites for targeted 
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analysis, normalized values over creatinine concentration (mg/L). Figure SF1: Schematic diagram illustrating 
the fingerprinting work-flow. 
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